Hailin Liu - Publications

NSUN2-mediated m5C modification of E2F1 promotes lung adenocarcinoma progression via the RAD54L signaling axis.

Journal: Respiratory research

Published: February 12, 2026

Identification of biomarkers based on ubiquitin-correlated genes for predicting immune profile and drug sensitivity in lung adenocarcinoma.

Journal: Frontiers in pharmacology

Published: June 13, 2025

Public Transcriptomic Data Mining for SCLC: From Candidate Ma rkers to Therapeutic Exploration.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: April 13, 2025

Nuclear to Cytoplasmic Transport Is a Druggable Dependency in HDAC7-driven Small Cell Lung Cancer.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: October 22, 2024

ACT001 inhibited CD133 transcription by targeting and inducing Olig2 ubiquitination degradation.

Journal: Oncogenesis

Published: June 05, 2022

Tumor-associated macrophages (TAMs)-derived osteopontin (OPN) upregulates PD-L1 expression and predicts poor prognosis in non-small cell lung cancer (NSCLC).

Journal: Thoracic cancer

Published: July 15, 2021

Long Noncoding RNA LINC01006 Facilitates Cell Proliferation, Migration, and Epithelial-Mesenchymal Transition in Lung Adenocarcinoma via Targeting the MicroRNA 129-2-3p/CTNNB1 Axis and Activating Wnt/β-Catenin Signaling Pathway.

Journal: Molecular and cellular biology

Published: March 23, 2021

Anlotinib suppresses lymphangiogenesis and lymphatic metastasis in lung adenocarcinoma through a process potentially involving VEGFR-3 signaling.

Journal: Cancer biology & medicine

Published: January 17, 2020

Clinical importance of VEGFC and PD-L1 co-expression in lung adenocarcinoma patients.

Journal: Thoracic cancer

Published: December 16, 2019

miR‑195 suppresses metastasis and angiogenesis of squamous cell lung cancer by inhibiting the expression of VEGF.

Journal: Molecular medicine reports

Published: September 10, 2018

EGFR T790M detection and osimertinib treatment response evaluation by liquid biopsy in lung adenocarcinoma patients with acquired resistance to first generation EGFR tyrosine kinase inhibitors.

Journal: Diagnostic pathology

Published: May 21, 2018

Whole-exome sequencing identifies key mutated genes in T790M wildtype/cMET-unamplified lung adenocarcinoma with acquired resistance to first-generation EGFR tyrosine kinase inhibitors.

Journal: Journal of cancer research and clinical oncology

Published: March 03, 2018